glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated Drug mechanism of action of analogues, DPP-IV inhibitors, Mechanism of action for GIP,
Description
Lean ME, Carraro R, Finer N, et al
the limited number of observed cases prevents a more accurate assessment of the effects of treatment in different patient populations
Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints
GLP-1 and cartilage protection
